erature are predominantly pediatric, 3, 8, 25 there might be a difference in the tumor biology and the clinical course in adult patients compared to children. Histologically, these case series are made up of very few samples of low-grade astrocytomas (pilocytic astrocytoma, WHO grade I). Even in the cases of radiographic disease progression, further therapy like stereotactic radiation or chemotherapy was usually implemented without a histological diagnosis.
In general, tectal gliomas, including intrinsic diffuse astrocytomas or pilocytic astrocytoma, are assumed to have a favorable prognosis as they are mostly considered indolent lesions, especially in children. 5, 25 Occlusive hydrocephalus is most often the presenting symptom that requires surgical treatment. 5, 9, 14 If the hydrocephalus is adequately treated, patients are typically followed up by MRI and clinical examination. Potential parameters to predict a progressive course have not yet been accurately described in the literature.
We present here a subgroup of patients whose tumors demonstrated growth progression and subsequent malignant transformation. Moreover, this article emphasizes the correlation between MRI findings, time to tumor progression, and histological diagnosis as well as the role of quality-of-life assessment in this patient group. Our analysis subsequentially focuses on the discussion of current clinical management guidelines for patients with tectal gliomas.
Methods

Patients
We performed a retrospective analysis on data from 23 patients with tumors of the tectum mesencephali treated at our institution from 1979 to 2016. Patients were identified from case records and surgical protocol archives. The diagnosis was verified by neuroradiological criteria and reports. We included all patients with radiographic presentation suspicious for a glioma with clear association to the tectum mesencephali. Patients with regressive lesions, indicative of inflammation, and patients with lesions that were histologically proven to be entities other than glioma were excluded. "Tectal" was defined for the purpose of this study as primarily emanating from the quadrigeminal plate or extending beyond it but with the primary mass in the tectum. Periaqueductal tumors incorporating the tectum were included. Pineal lesions, which frequently displace and distort the tectum, were not included, 28 nor were diffuse intrinsic pontine gliomas (DIPGs), which may have upward extension into upper brainstem structures. In 12 cases, the patients responses to quality-of-life questionnaires (EORTC QLQ C30 rev. 3.0 and BN20) were documented for routine evaluation and quality assessment of health-related quality of life during clinical follow-up contacts. Data analysis was performed retrospectively on anonymized clinical data sets. The study was conducted in accordance with ethical guidelines of the Hamburg (Germany) ethics review board and with ethics guidelines of the Declaration of Helsinki.
Radiographic Evaluation
MRI contrast enhancement was analyzed on T1-weighted images obtained after administration of a contrast agent. In a subgroup of patients, the first imaging assessment was undertaken using CT, as MRI was not available at that time. Tumor size was calculated from measurements of axial and sagittal T2-weighted MR images. Tumor growth progression and occurrence of contrast enhancement over the disease course were evaluated by an independent neuroradiologist.
Statistical Analysis
Statistical analysis was performed using chi-square and Student t-tests in Microsoft Excel 2016 and IBM SPSS version 24. Significance was defined on a 95% confidence interval. Graphical analysis of growth progression and contrast enhancement parameters was performed using GraphPad Prism. The quality-of-life results were compared to published cohorts using the Student t-test. Differences in the survival analysis were calculated using a Mantel-Cox log-rank test.
Results
Patient Cohort
Twenty-three patients with suspected tectal glioma were identified. Their mean age at diagnosis was 29 years (range 1-69 years); 10 patients were under the age of 18 years at the time of initial diagnosis. The mean duration of follow-up was 73 months (range 7-429 months). Twelve patients (52.2%) were male, and 11 (47.8%) were female. Their primary signs and symptoms on admission were hydrocephalus (78%), visual impairment (26%), cephalgia (13%), gait disturbances (8.7%), facial dysesthesia (4.3%), primary amenorrhea (4.3%), epilepsy (8.7%), and developmental delay (4.3%). Patient demographic and clinical characteristics are summarized in Table 1 and Fig. 1 .
Magnetic Resonance Imaging
In 7 cases (30.4%), the tumors showed contrast enhancement on initial MRI. In 5 of the remaining cases (21.7% of the overall cohort), the tumors developed contrast enhancement during follow-up (example in Fig. 2A ). Excluding patients with primary enhancement at initial diagnosis, the mean time to contrast enhancement was 127.2 months (SD 50.3 months, p < 0.05, Fig. 3A) . In addition, 11 of 23 (47.8%) patients showed signs of tumor progression (e.g., increase in size), based on T2-weighted MRI during the observation period (mean time to progression 87.5 months, SD 120.0 months, p < 0.05). Within the limited group of patients with growth progression, primary contrast-enhancing tumors showed a faster time to progression (mean 35.33 months, SD 19.69 months) than tumors that developed enhancement after initial diagnosis (secondary enhancement; mean time to progression 136 months, SD 39.14 months), whereas both groups had faster time to growth progression than nonenhancing tumors did (p = 0.024, Mantel-Cox log-rank test, Fig. 3B ).
Primary aqueduct stenosis was present in 19 (82.6%) patients, resulting in hydrocephalus in 18 (78.3%) cases. The tumor volume at diagnosis ranged from 0.1 to 49.1 cm , p < 0.05). As expected, patients with hydrocephalus had a significantly higher mean tumor volume than those without hydrocephalus (7.6 vs 1.5 cm 3 , p < 0.05).
Treatment
Nine patients (39.1%, n = 9/23) underwent tumor resection (25.7%, n = 9/35, 7 subtotal, 2 gross total). Overall, 6 patients (26.1%, n = 6/23) were biopsied (2 of those twice due to inconclusive histology), out of which 3 patients (13.1%, n = 3/23) received a biopsy followed by resection (histology: GBM, grade IV, in 2 cases; anaplastic astrocytoma, grade III, in 1 case) and 3 patients received a biopsy only. Histological analysis in the biopsy-only group showed 2 pilocytic astrocytomas, WHO grade I, and 1 anaplastic astrocytoma, WHO grade III, which was not amenable to resection and was treated with chemotherapy. In six patients (26.1%, n = 6/23) a primary resection and histological confirmation was performed. About half of all patients (47.8%, n = 11/23) did not receive surgical histological confirmation by biopsy or resection and were followed with regular MRI.
Eighteen patients had hydrocephalus at presentation. For the treatment of hydrocephalus, 2 patients (8.7%, n = 2/23) received a cerebrospinal fluid shunt only, 8 patients underwent endoscopic third ventriculostomy only (34.8%, n = 8/23), and 4 patients (17.4%, n = 4/23) underwent both endoscopic third ventriculostomy and ventriculoperitoneal shunting. Four patients did not need additional surgery for hydrocephalus after resection.
Two patients received combined radiochemotherapy after tumor resection, 1 patient underwent radiation therapy (without chemotherapy) postoperatively, and 2 received chemotherapy after biopsy.
Of those patients showing tumor progression, those who had undergone tumor resection showed progression at mean of 68.4 months after initial presentation (vs 103.5 months without resection, no significant difference). However, enhancement in progressing tumors was seen at a mean of 118.0 months in patients who were not initially treated with resection and 93.0 months in those who were (no significant difference). Patients whose tumors showed no contrast enhancement at initial presentation but showed enhancement on subsequent follow up demonstrated a delay in mean time to progression when they underwent tumor resection. Hydrocephalus occurred at a mean of 62.3 months in patients without tumor resection as compared with 143.0 months in patients with resection (n = 2 vs n = 3, p = 0.3). Similarly, the mean time to enhancement was 99.7 versus 168.5 months (n = 3 vs n= 2, p = 0.12). This supports the concept of early surgical intervention, as the patient course otherwise shows earlier progression.
Two patients (8.7%) died after a mean of 14.6 years due to malignant transformation and rapid tumor growth (Fig. 1) . In both cases, histological findings revealed glioblastoma multiforme (GBM) WHO grade IV. In 1 case (patient 2), 2 samples of the histological progress were available-one after initial biopsy (WHO grade II) and one after subtotal resection (WHO grade IV)-within the course of clinical progression (Fig. 1) .
In the few cases in which subtotal tumor resection was performed, no major surgical complications were observed. Malfunction of ventriculoperitoneal shunts or infections due to external ventricular drainage did not differ from the known complication rates for these procedures.
Histology
Histological findings were available for 12 cases, of which 7 were classified as low-grade (LG) tumors (5 pilocytic astrocytomas, grade I; 1 ganglioglioma, grade I; 1 diffuse astrocytoma, grade II) and 5 as high-grade (HG) tumors (3 GBMs, grade IV; and 2 anaplastic astrocytomas, grade III). Histological grades describe the last tested tumor grade during the disease course. Interestingly, primary contrast enhancement was found in 5 (71.4%) of 7
LG tumors and 2 (40.0%) of 5 HG tumors (Table 1) . Immunohistochemical staining for isocitrate dehydrogenase 1 mutation (IDH1 R132H) was negative in all 4 of the HG tumors in which it was performed. In addition, in retrospect, 1 anaplastic astrocytoma, grade III (tested 3/5 HG tumors) showed an H3 K27 M mutation, indicating a diffuse midline glioma, WHO grade IV. All HG tumors eventually showed enhancement, as did 5 of 7 (71.4%) of the histologically confirmed LG tumors. Interestingly, secondary enhancement occurred at 189.0 months in 1 patient with initial diagnosis of diffuse astrocytoma, grade II, which subsequently progressed to glioblastoma, grade IV; no information on the ganglioglioma patient's time of enhancement was present in the record. The mean time to enhancement in the HG cohort was 87.0 months. Progression occurred in 3 of 7 (33.3%) LG versus 4 of 5 (80.0%) HG tumors. The mean time to progression was 15.5 months for histologically diagnosed LG and 76.5 months for HG tumors. The patients' disease course and time points of biopsy/resection are summarized in Fig. 1 .
Quality of Life
During routine clinical follow-up contacts, records for 12 patients (mean age 53.8 years) included questioning regarding quality of life. Two validated questionnaires for cancer patients were applied. EORTC-QLQ-C30 and EORTC-QLQ-BN20 scores (mean %) are shown in Tables 2 and 3 . Health-related quality-of-life scores were compared to scores for the healthy population, 13 scores for glioma and metastatic brain cancer patients, 4, 16, 26 and scores for long-term survivors of pediatric gliomas, which included WHO grade I (57%) and II (43%) tumors of various locations (Tables 2 and 3 ).
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In comparison to the healthy controls, tectal glioma patients had presented significant differences in scores for emotional functioning (mean 77.3 vs 32.2, p < 0.01), cognitive functioning (75.8 vs 90.5, p < 0.01), social functioning (68.2 vs 31.5, p < 0.01) and financial difficulties (18.2 vs 5.7, p < 0.01) ( Tables 2 and 3) . 13 When compared to a general cohort of patients with newly diagnosed high-grade glioma (n = 745, two phase III EORTC/NCIC trials), vs 37.5, p < 0.05), 4 loss of appetite (0.0 vs 19.5, p < 0.01), and bladder function (36.0 vs 11.1, p < 0.01) were significantly worse in our tectal glioma patients. In comparison to a cohort of long-term survivors of pediatric low-grade glioma, our tectal glioma patients scored significantly worse for social functioning (68.7 vs 87.0, p < 0.05), and drowsiness was more common (37.9 vs 20.0, p < 0.05) in the tectal glioma patients, as was weakness of legs (21.6 vs 8.0, p = 0.05) and bladder dysfunction (36.0 vs 9.0, p < 0.01). The pediatric group had significantly lower scores for future uncertainty (0.0 vs 18.8, p < 0.01).
Discussion
The rare prevalence and heterogeneous nature of tectal lesions has rendered the treatment debate of this entity controversial. Due to the small size of the tectal anatomical region, tectal gliomas represent a rare and heterogeneous pathology, as this report shows. Hence, no unique treatment approach has been defined, and most likely none even can be defined. In this context, we contribute our substantial series of patients diagnosed with intrinsic tectal gliomas, analyzed their clinical course, and discuss the highlighted potential for malignant transformation. Furthermore, since neuropsychological impairment represents a key parameter in the outcome of the more prevalent pediatric tectal glioma, we included a quality of life assessment to emphasize an additional clinical aspect of importance in this unique tumor entity.
Initial considerations of tectal lesions mainly concern the management of hydrocephalus. As expected, due to their anatomical vicinity to the sylvian aqueduct the primary symptom leading to the initial diagnosis in our cohort was third ventricle hydrocephalus. It has been found acceptable to solely treat the hydrocephalus-using shunts or more recently endoscopic third ventriculostomy. 15, 19, 23, 27 Our series indicates that this may be sufficient for some patients, but a priori it cannot be expected that a tectal lesion will remain inert, as some smaller series have shown for pediatric patients. 3, 25 Within larger cohorts it has been found that tumors increase in size, leading to local compression, and also may show malignant degeneration requiring additional treatment to extend control and improve survival. 11, 20 After initial management of hydrocephalus, the diagnostic discussion focuses on the histological diagnosis. If hydrocephalus symptoms develop gradually and third ventriculostomy can be planned in a semi-elective time frame, concurrent biopsy can be performed. However, due to the histological heterogeneity of these tumors and the possibility of obtaining nonrepresentative areas, endoscopic biopsy can be considered inferior to stereotactic biopsies, which has demonstrated superior accuracy (98% vs 78%). 2 In addition, stereotactic biopsy demon- LGG = low-grade glioma; NS = not statistically significant; ped = pediatric; pts = patients. Individual category scores (%) of the different cohorts were tested against our tectal glioma cohort; p values were calculated using unpaired t-test and were included if beneath 90% CI for informative purposes.
* Pediatric cohort. Individual category scores (%) of the different cohorts were tested against our tectal glioma cohort; p values were calculated using unpaired t-test and were included if beneath 90% CI for informative purposes.
* Pediatric cohort.
strated a trend toward a lower complication rate. 1 Histological confirmation was pursued in 52.2% of patients in our cohort, and the rates of histological yield were 66.7% and 100% after the first and second biopsy, respectively. Although histological confirmation is desirable, invasive diagnostic can be postponed depending on the tumor's size and growth behavior, which will have to be assessed repetitively by MRI. If lesions appear suitable for resection, the open surgical approach achieves the most accurate diagnosis and will allow adjustment of the extent of resection according to the intraoperative results obtained from cryosections. To surgically access tectal lesions most surgeons prefer the same supracerebellar approach as for pineal lesions. 21, 24 Additional routes have been discussed, depending on the extent of the tumor. 12, 17 However, treating these lesions with aggressive surgery is controversial, and because of the location any surgical intervention is complex and harbors the risk for incapacitating complications. The most common complications include diplopia or upward gaze (Parinaud's syndrome) due to additional irritation of the quadrigeminal plate or postoperative pneumocephalus, if surgery was performed in the sitting position. 6 Our case series demonstrates that, although postoperative symptoms were present, most were transient and did not result in longterm morbidity. Nevertheless, surgical removal of tectal lesions should be reserved for centers that have established sufficient neurosurgical expertise.
Tectal gliomas make up approximately 8% of all brainstem gliomas, reflecting the small mass of tissue.
11 While brainstem gliomas have been described as progressive lesions with an unfavorable prognosis, 11 tectal lesions are mostly considered benign and inert lesions possibly because of a different biology or an anatomical environment which is less critical than the dense long fiber tracts in the brain stem. Unfortunately, given the overall low prevalence and lack of larger case series, no clear histopathological diagnosis or pathophysiological basis was identified. Fisher et al. categorized into pilocytic and fibrillary astrocytoma for brainstem gliomas. 7 In our series, about half of the histologically confirmed tumors were WHO grade I tumors and the other half demonstrated anaplastic de-differentiation (WHO grades III and IV). Interestingly, in our series higher-grade tumors presented less frequently with contrast enhancement at initial diagnosis, although this radiographic feature is associated with poor prognosis and early tumor progression as reproduced by our data. Although the tested high-grade tumors did not show positivity for IDH1 R132H mutation, this finding points toward a progressive de-differentiation and evolution from lower-grade (WHO grade II) histology within patients with high-grade tumors. More importantly, we retrospectively identified 1 anaplastic astrocytoma (WHO grade III) as H3 K27 M mutated. This illustrates that the ability to perform molecular diagnostics could enhance the diagnostic precision of biopsies and increase the value of histological confirmation. Since most patients are monitored using repetitive longitudinal MRI, the prevalence of high-grade histologies is subject to bias, as patients typically undergo biopsy because of either suspicious contrast enhancement or growth progression. Nevertheless, 5 of 23 (21.7%) patients presented with highgrade lesions-a significant proportion of patients with a malignant disease course. This raises the question of whether early biopsy and histological confirmation should be desirable for all tectal lesions and if MRI intervals, or even early treatment approaches, including radiotherapy, should be adopted depending on the histology.
Securing a definite diagnosis could also help patients to psychologically cope with their disease, as clinical experience has shown that patients with tectal gliomas suffer from tremendous psychological stress, which increases repeatedly with the approach of MRI appointments. This observation was confirmed in our quality-of-life assessment. Here, tectal glioma patients showed significant impairments in social, cognitive, and emotional functioning compared to healthy controls; 13 in most cases, these differences were probably mediated by the overall psychological sequelae of the diagnosis and not the result of functional impairment caused directly by the tumor. This finding is supported by the fact that tectal glioma patients scored significantly better on questions related to insomnia and appetite loss compared to patients with metastasis, 4 and also by the fact that they scored better on questions related to seizures than nontectal glioma patients did. 16 The predominant somatic symptom in tectal glioma patients was drowsiness. Future uncertainty was documented in approximately 18% of interviewed patients. This finding can be interpreted controversially, as it is unclear how patients received and interpreted information on their prognosis, which in addition might be influenced by the widespread opinion of an overall indolent lesion. The findings of a prevalent malignant transformation of tectal lesions presented here should therefore be handled cautiously when providing information to patients and in the clinical management throughout follow-up, as the perception of an unpredictable threat can result in significant psychological morbidity in this patient cohort.
Our study was limited by the retrospective nature and due to the overall rare prevalence and clinical heterogeneity of this type of lesion. Individual assessments in the quality-of-life questionnaires were subject to bias, as not all patients were available to participate in this part of the study. In analogy, biopsies were predominantly taken from lesions that appeared large, suspicious, or progressive lesions on MRI, and therefore do not yield histological grading that is representative for all tectal lesions. Although the size of our cohort exceeds that of most published case series, the heterogeneity within the patient population does not allow for the postulation of general recommendations. Nevertheless, our observations demonstrate that malignant transformation is a prevalent feature of tectal gliomas. In this context, histological confirmation should be performed if feasible, as recommendations for radiological monitoring and psychological guidance during follow-up management can be affected by the tumor type.
Conclusions
This study finds tectal gliomas to be a relatively unpredictable and heterogeneous subgroup. Early and rapid clinical and radiographic progression do not always occur simultaneously, and detection of early signs of possible malignant transformation is crucial. Thus, performing a biopsy to obtain a histological diagnosis should be the rule rather than the exception-not least in the light of molecular pathology, emerging targeted therapies, and improved stereotactic radiation therapy.
